PaxMedica (NASDAQ:PXMD – Get Free Report) is projected to release its resultson Wednesday, September 2nd. Analysts expect the company to post earnings of ($0.88) per share for the quarter.
PaxMedica Price Performance
PaxMedica stock opened at $0.00 on Tuesday. The stock has a market capitalization of $7,918.40, a PE ratio of -0.00 and a beta of -0.99. PaxMedica has a 12-month low of $0.00 and a 12-month high of $0.02.
PaxMedica Company Profile
PaxMedica, Inc is a clinical‐stage biopharmaceutical company headquartered in Burlingame, California. The company is dedicated to developing novel therapies for central nervous system disorders, with a particular emphasis on addressing unmet needs in autism spectrum disorders, mood disorders and related behavioral conditions. PaxMedica focuses on small-molecule candidates designed to modulate key neural pathways implicated in social and emotional regulation.
The company’s lead development program centers on arbaclofen, a proprietary formulation intended to improve social functioning in patients with autism spectrum disorders and associated behavioral challenges.
Further Reading
- Five stocks we like better than PaxMedica
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for PaxMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PaxMedica and related companies with MarketBeat.com's FREE daily email newsletter.
